Shanghai, China

Fen Ren

This inventor holds 1 USPTO granted patent and 2 published patent applications. Top assignee: Shanghai Aucta Pharmaceuticals Co., Ltd.. Active years: 2025.

USPTO Granted Patents = 1 

% Patents Active = 100.0

Average Co-Inventor Count = 4.0

ph-index = 1


Company Filing History:


Years Active: 2025

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Fen Ren - Innovator in Pharmaceutical Formulations

Introduction

Fen Ren is a notable inventor based in Shanghai, China. He has made significant contributions to the field of pharmaceuticals, particularly in the formulation of medications. His innovative approach has led to the development of a unique dosage form that enhances drug delivery and efficacy.

Latest Patents

Fen Ren holds a patent for a formulation of lacosamide. The patent document discloses a dosage form featuring a unique combination of extended-release and immediate-release components of the active ingredient. This innovative dosage form allows for high drug loading, enabling once-daily administration while providing a sustained window of effective treatment with reduced fluctuations in drug concentration. The document also outlines a method for treating neurological or psychiatric diseases or conditions in a subject.

Career Highlights

Fen Ren is associated with Shanghai Aucta Pharmaceuticals Co., Ltd., where he applies his expertise in pharmaceutical formulations. His work has been instrumental in advancing treatment options for patients with neurological conditions.

Collaborations

Fen Ren collaborates with talented professionals in his field, including Ye Huang and Bolun Zhang. Their combined efforts contribute to the ongoing development of innovative pharmaceutical solutions.

Conclusion

Fen Ren's contributions to pharmaceutical formulations exemplify the impact of innovation in medicine. His work continues to pave the way for improved treatment options for patients worldwide.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…